Cargando…

Ailanthone: A novel potential drug for treating human cancer

Cancer is the second leading cause of death after cardiovascular disease. In 2015, >8.7 million people died worldwide due to cancer, and by 2030 this figure is expected to increase to ~13.1 million. Tumor chemotherapy drugs have specific toxicity and side effects, and patients can also develop se...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Haixiang, Yu, Xiuchong, Hang, Chen, Gao, Kaijun, Lao, Xifeng, Jia, Yangtao, Yan, Zhilong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377054/
https://www.ncbi.nlm.nih.gov/pubmed/32724391
http://dx.doi.org/10.3892/ol.2020.11710
_version_ 1783562148043030528
author Ding, Haixiang
Yu, Xiuchong
Hang, Chen
Gao, Kaijun
Lao, Xifeng
Jia, Yangtao
Yan, Zhilong
author_facet Ding, Haixiang
Yu, Xiuchong
Hang, Chen
Gao, Kaijun
Lao, Xifeng
Jia, Yangtao
Yan, Zhilong
author_sort Ding, Haixiang
collection PubMed
description Cancer is the second leading cause of death after cardiovascular disease. In 2015, >8.7 million people died worldwide due to cancer, and by 2030 this figure is expected to increase to ~13.1 million. Tumor chemotherapy drugs have specific toxicity and side effects, and patients can also develop secondary drug resistance. To prevent and treat cancer, scientists have developed novel drugs with improved antitumor effects and decreased toxicity. Ailanthone (AIL) is a quassinoid extract from the traditional Chinese medicine plant Ailanthus altissima, which is known to have anti-inflammatory and antimalarial effects. An increasing number of studies have focused on AIL due to its antitumor activity. AIL can inhibit cell proliferation and induce apoptosis by up- or downregulating cancer-associated molecules, which ultimately leads to cancer cell death. Antitumor effects of AIL have been observed in melanoma, acute myeloid leukemia, bladder, lung, breast, gastric and prostate cancer and vestibular neurilemmoma. To the best of our knowledge, the present study is the first review to describe the antitumor mechanisms of AIL.
format Online
Article
Text
id pubmed-7377054
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-73770542020-07-27 Ailanthone: A novel potential drug for treating human cancer Ding, Haixiang Yu, Xiuchong Hang, Chen Gao, Kaijun Lao, Xifeng Jia, Yangtao Yan, Zhilong Oncol Lett Review Cancer is the second leading cause of death after cardiovascular disease. In 2015, >8.7 million people died worldwide due to cancer, and by 2030 this figure is expected to increase to ~13.1 million. Tumor chemotherapy drugs have specific toxicity and side effects, and patients can also develop secondary drug resistance. To prevent and treat cancer, scientists have developed novel drugs with improved antitumor effects and decreased toxicity. Ailanthone (AIL) is a quassinoid extract from the traditional Chinese medicine plant Ailanthus altissima, which is known to have anti-inflammatory and antimalarial effects. An increasing number of studies have focused on AIL due to its antitumor activity. AIL can inhibit cell proliferation and induce apoptosis by up- or downregulating cancer-associated molecules, which ultimately leads to cancer cell death. Antitumor effects of AIL have been observed in melanoma, acute myeloid leukemia, bladder, lung, breast, gastric and prostate cancer and vestibular neurilemmoma. To the best of our knowledge, the present study is the first review to describe the antitumor mechanisms of AIL. D.A. Spandidos 2020-08 2020-06-09 /pmc/articles/PMC7377054/ /pubmed/32724391 http://dx.doi.org/10.3892/ol.2020.11710 Text en Copyright: © Ding et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Ding, Haixiang
Yu, Xiuchong
Hang, Chen
Gao, Kaijun
Lao, Xifeng
Jia, Yangtao
Yan, Zhilong
Ailanthone: A novel potential drug for treating human cancer
title Ailanthone: A novel potential drug for treating human cancer
title_full Ailanthone: A novel potential drug for treating human cancer
title_fullStr Ailanthone: A novel potential drug for treating human cancer
title_full_unstemmed Ailanthone: A novel potential drug for treating human cancer
title_short Ailanthone: A novel potential drug for treating human cancer
title_sort ailanthone: a novel potential drug for treating human cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377054/
https://www.ncbi.nlm.nih.gov/pubmed/32724391
http://dx.doi.org/10.3892/ol.2020.11710
work_keys_str_mv AT dinghaixiang ailanthoneanovelpotentialdrugfortreatinghumancancer
AT yuxiuchong ailanthoneanovelpotentialdrugfortreatinghumancancer
AT hangchen ailanthoneanovelpotentialdrugfortreatinghumancancer
AT gaokaijun ailanthoneanovelpotentialdrugfortreatinghumancancer
AT laoxifeng ailanthoneanovelpotentialdrugfortreatinghumancancer
AT jiayangtao ailanthoneanovelpotentialdrugfortreatinghumancancer
AT yanzhilong ailanthoneanovelpotentialdrugfortreatinghumancancer